RESULTS:
Each patients’ response to treatment was unique. P1 had a complete
response beginning with the third dose of the treatment. P2 showed a
partial response to the treatment after the second dose. Despite 8 doses
of the treatment, P3 did not achieve remission. All patients’ serum AAT
levels were in normal ranges before the treatment. Only P1’s serum AAT
level increased gradually and was found to be the highest after the
final dose. Other patients’ serum AAT levels didn’t change during
treatment. (Table 4) Distinctly, there was an increase in the proportion
of CD4+ CD25+FoxP3+ lymphocytes in all of the patients.